Physician Notes: Clinical Studies May Be at Risk for Kickback Attacks

Why This Topic Matters

It helps readers understand how federal fraud-and-abuse oversight can affect clinical research financing and why cost-sharing practices in research settings remain sensitive. It also highlights broader Medicare reimbursement changes that may influence pharmacy operations and transplant care.

Article Sections

1. OIG advisory opinion on clinical trial cost-sharing

   Discusses a federal advisory opinion involving a clinical research arrangement, Medicare coverage of trial-related expenses, and anti-kickback concerns. The section focuses on compliance context and the narrowness of the opinion's reach.

2. Malpractice reform campaign news

   Summarizes a legal and political advocacy effort related to medical malpractice liability limits. The section notes the campaign's planned outreach and target states.

3. Medicare drug payment changes and transplant patients

   Covers a Medicare reimbursement update affecting prescription drug payment levels and the possible implications for transplant patients and pharmacies. The section also mentions responses by drug manufacturers and Medicare administrators.